Conexeu Sciences (CNXU) has drawn fresh attention after expanding its board and executive team, including naming co founder David Bogart as Chief Commercial Officer, as it moves its CXU wound care platform toward FDA 510(k) preparation.

Recent appointments around the CXU platform come after a period of mixed trading, with a 7 day share price return of 17.63% and a 30 day share price return that declined 7.78% from a latest close of $13.28. This leaves year to date share price gains of 1.61% and suggests that momentum has picked up again in the very short term.

If you are looking beyond Conexeu Sciences for other opportunities in high growth areas, this is a useful moment to scan the market using the 40 healthcare AI stocks.

With Conexeu Sciences still pre revenue, loss making and only at the FDA preparation stage, recent share price swings raise a key question for you: is this stock undervalued or is the market already pricing in future growth?

Most Popular Narrative: 47.6% Undervalued

According to the most followed narrative on Conexeu Sciences, a fair value of $25.34 versus the recent $13.28 share price implies a wide valuation gap that hinges on CXU’s wound care potential.

Conexeu may be starting with wound care, but CXU’s applications extend far beyond that alone, and the company is intentional about its roadmap.

Dental, veterinary, and 3D bioink follow as horizontal expansion opportunities. Aesthetics comes even later as the high margin opportunity.

Want to understand why this narrative treats wound care as just the opening act? The key assumptions sit in multi market revenue expansion and future profitability expectations.

Result: Fair Value of $25.34 (UNDERVALUED)

However, this Conexeu Sciences narrative still hinges on FDA acceptance of the 510(k) route and future financing, either of which could quickly weaken the bullish case.

Another View: Conexeu Sciences Looks Expensive On P/B

The earlier user narrative suggested Conexeu Sciences could be 47.6% undervalued based on a hypothetical revenue multiple. However, the current 49.2x P/B ratio is far above both the US Biotechs industry at 2.5x and peers at 7.7x, which points to a high valuation and limited margin for error.

Next Steps

If the mix of bullish and cautious views around Conexeu Sciences feels hard to balance, take a close look at the underlying figures and risks yourself. A good place to start is the 2 important warning signs.

Looking for more ideas beyond Conexeu Sciences?

If Conexeu Sciences has sharpened your interest in new opportunities, do not stop here. Use the Simply Wall St Screener to surface other focused ideas that might suit your portfolio.

• Target reliable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (48 results) that pair financial strength with consistent fundamentals.
• Hunt for mispriced opportunities by scanning the 45 high quality undervalued stocks where quality businesses trade below their assessed worth.
• Secure potential income streams by checking out the 8 dividend fortresses that focuses on higher yield companies with resilient payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.